Instil Bio, INC 10-Q quarterly reports

Instil Bio's Q1 2026 Form 10-Q filing reveals a net loss of $4.2 million, a significant reduction from the prior year, alongside strategic shifts and ongoing liquidity concerns.

Instil Bio, a clinical-stage biopharmaceutical company, reported a net loss of $13.6 million for Q3 2025, while advancing its lead bispecific antibody candidate, 2510, into a U.S. Phase 1 clinical trial for solid tumors.

Instil Bio, a clinical-stage biopharmaceutical company, reported increased net losses but reduced cash burn from operations, driven by strategic restructuring, a new lead product candidate, and an extended cash runway beyond 2026.

Instil Bio's Q1 2025 results reveal a net loss of $28.2 million, impacted by restructuring and impairment charges related to facility sales and strategic shifts.

Instil Bio reports a net loss of $23.0 million for the third quarter of 2024, alongside updates on its strategic collaborations and financial position.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ended June 30, 2024, highlighting a net loss of $14.9 million and providing updates on its strategic reprioritization and recent licensing agreement.

Instil Bio reports a net loss of $24.3 million for the first quarter of 2024, alongside ongoing restructuring efforts and a strategic shift in clinical development.